<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Previously we demonstrated the neuroprotective effect of <z:chebi fb="0" ids="50730">montelukast</z:chebi>, a <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi> <z:chebi fb="0" ids="25029">leukotriene</z:chebi> receptor-1 (CysLT(1) ) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on <z:hpo ids='HP_0011009'>acute</z:hpo> brain injury after focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in mice </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we have determined its effect on <z:hpo ids='HP_0011010'>chronic</z:hpo> brain injury after focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in mice and rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: After transient focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, <z:chebi fb="0" ids="50730">montelukast</z:chebi> was intraperitoneally injected in mice or orally administered to rats for five days </plain></SENT>
<SENT sid="3" pm="."><plain>Behavioural dysfunction, brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> and neuron loss were determined to evaluate <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>KEY FINDINGS: <z:chebi fb="0" ids="50730">Montelukast</z:chebi> (0.1 mg/kg) attenuated behavioural dysfunction, brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> and neuron loss in mice, which was similar to pranlukast, another CysLT(1) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Oral <z:chebi fb="0" ids="50730">montelukast</z:chebi> (0.5 mg/kg) was effective in rats and was more effective than <z:chebi fb="0" ids="31530">edaravone</z:chebi>, a free radical scavenger </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="50730">Montelukast</z:chebi> protected mice and rats against <z:hpo ids='HP_0011010'>chronic</z:hpo> brain injury after focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, supporting the therapeutic potential of CysLT(1) receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
</text></document>